Patient and doctor


We focus on developing therapies against targets where existing preclinical and early clinical data is available. This data can give a strong indication that a therapy will disrupt a targeted biochemical process and improve patient outcome without significant side-effects. Sareum’s approach is lower risk than developing therapies against entirely novel targets.

We currently have one development programme (Chk1) in two Phase I clinical trials, being conducted by licence partner Sierra Oncology and another (Aurora+FLT3) in preclinical development, in collaboration with Hebei Medical University Biomedical Engineering Company (HMUBEC).

Development Programmes Jun16

Click here for our latest research update